



Nutrición Hospitalaria



Trabajo Original

Otros

Malnutrition is a key prognostic factor related to high mortality-rate in patients with severe alcoholic hepatitis

La desnutrición es un factor pronóstico clave relacionado con elevada mortalidad en pacientes con hepatitis alcohólica severa

Fátima Higuera de la Tijera¹, Alfredo Servín Caamaño², Luis Servín Abad³ and José Luis Pérez Hernández¹

Departments of ¹Gastroenterology and ²Internal Medicine. Hospital General de México "Dr. Eduardo Liceaga". Mexico City, Mexico. ³Lakeland Regional Medical Center. Lakeland, Florida

Abstract

Background and aim: comparatively with European or North-American populations, severe alcoholic hepatitis has a high mortality rate in Mexican population, becoming as high as 50 to 81% in those classified as ABIC B or C; this is true even when they receive specific therapy with steroids or pentoxifylline. The aim of this study was to know which clinical factors are related to early mortality (first 30 days) in Mexican patients with severe alcoholic hepatitis.

Subjects and methods: this was a retrospective cohort study that included patients with severe alcoholic hepatitis, defined by a Maddrey's discriminant function ≥ 32 , treated at a tertiary care center in a period of five years (2010 to 2015).

Results: seventy-six patients were included, 72 (94.7%) were males, mean age was 43 ± 9.1 year-old, and 58 (76.3%) had also cirrhosis. According to the subjective global assessment (SGA), 38 (50%) had severe malnutrition, 22 (28.9%) were at risk of malnutrition, and 16 (21.1%) were well-nourished. At 30 days, 46 patients (60.5%) died. In the multivariate analysis, only the presence of severe malnutrition was associated with 30-day mortality: OR = 6.4; 95% CI: 1.9-22.1; $p = 0.003$.

Conclusions: the nutritional status seems to be a cardinal prognostic factor associated with early mortality (first 30 days). Malnutrition can explain the high mortality rate observed in Mexican patients with severe alcoholic hepatitis.

Key words:

Alcoholic hepatitis.
Malnutrition.
Mortality. Subjective global assessment.
Risk factors.

Resumen

Antecedentes: en comparación con otras poblaciones europeas o norteamericanas, la hepatitis alcohólica severa tiene una mortalidad muy elevada en población mexicana atendida en hospitales federales (generalmente, pacientes de medio socioeconómico bajo) y llega a alcanzar entre el 50% y el 81% en aquellos catalogados como ABIC B o C; esto es cierto a pesar del tratamiento específico con esteroide o pentoxifilina.

Objetivo: conocer qué factores clínicos están asociados a una mortalidad temprana (30 días) en pacientes mexicanos con hepatitis alcohólica severa.

Material y métodos: se realizó un estudio de cohorte histórica que incluyó a pacientes con hepatitis alcohólica severa, definida por una función discriminante de Maddrey mayor a 32, atendidos en el Hospital General de México durante un periodo de cinco años (2010-2015).

Resultados: se incluyeron 76 pacientes, de los cuales 72 (94,7%) fueron hombres, la media de edad fue de $43 \pm 9,1$ años; 58 (76,3%) de ellos tenían alteraciones sugestivas de cirrosis en el ultrasonido. De acuerdo con la valoración global subjetiva (VGS), 38 (50%) presentaban desnutrición grave, 22 (28,9%) se encontraban en riesgo de desnutrición y 16 (21,1%) estaban bien nutridos. La mortalidad global a 30 días en esta cohorte fue de 46 pacientes (60,5%). En un modelo multivariado, solo la desnutrición severa se asoció con mortalidad a 30 días: OR = 6,4; IC 95%: 1,9-22,1; $p = 0,003$.

Conclusión: el estado nutricional es el determinante más importante asociado a mortalidad temprana (30 días). La desnutrición severa explica claramente la elevada mortalidad que se observa en pacientes con hepatitis alcohólica severa, en población mexicana.

Palabras clave:

Hepatitis alcohólica.
Desnutrición.
Mortalidad. Valoración global subjetiva.
Factores de riesgo.

Received: 24/07/2017 • Accepted: 30/09/2017

Authors' contribution: Higuera de la Tijera F was the guarantor and designed the study; Servín Caamaño A and Pérez Hernández JL participated in the acquisition, analysis, and interpretation of the data; Higuera de la Tijera F wrote the manuscript; Servín Abad L reviewed the final manuscript and revised the article critically for important intellectual content. All the authors read and approved the final manuscript.

Higuera de la Tijera F, Servín Caamaño A, Servín Abad L, Pérez Hernández JL. Malnutrition is a key prognostic factor related to high mortality-rate in patients with severe alcoholic hepatitis. *Nutr Hosp* 2018;35:677-682

DOI: <http://dx.doi.org/10.20960/nh.1458>

Correspondence:

Fátima Higuera de la Tijera. Department of Gastroenterology and Hepatology, Hospital General de México "Dr. Eduardo Liceaga". 06726 Mexico City, Mexico
e-mail: fatimahiguera@yahoo.com.mx

INTRODUCTION

Comparatively with European or North-American populations, severe alcoholic hepatitis (SAH) has a very high mortality rate in Mexican population, being as high as 50 to 81% in those classified as Age-Bilirubin-INR-Creatinine score (ABIC) B or C; this is true in spite of specific treatment with steroids or pentoxifylline (1).

Recently, STOPAH trial demonstrated that neither steroid nor pentoxifylline treatment has a significant impact on the long-term mortality-rate of patients with SAH. But steroids can be helpful to improve 30-day survival in these patients (2).

Risk factors associated with early mortality in patients with SAH are: age, raise on serum creatinine, hyperbilirubinemia, leukocytosis, and alcohol intake > 120 g/day (1). One of the most important factors related to 30-day mortality is the development of acute renal failure (ARF); moreover, the amount of alcohol intake (median 219 g/day) is related to the development of ARF. The development of two or three simultaneous complications, such as ARF, hepatic encephalopathy, or variceal bleeding, increase the mortality risk in patients with SAH (3).

The liver failure is a condition that accelerates starvation; therefore, malnutrition is a common complication of liver disease. The prevalence of clinically significant malnutrition varies from 65% to 100% among patients with chronic liver disease (4). Malnutrition as a risk factor associated with mortality in patients with SAH has been evaluated in a few studies (5-7), but never was evaluated specifically in Mexican patients, a population with a high early mortality-rate (1,3).

The aim of this study was to explore which clinical factors are related to early mortality (at 30 days) in a population with a high mortality rate despite specific therapy for SAH, and to identify if malnutrition has influence in survival of patients with SAH.

SUBJECTS AND METHODS

TYPE OF STUDY AND SELECTION CRITERIA

A retrospective cohort study, which included patients with SAH, defined by a Maddrey's discriminant function ≥ 32 , attended at tertiary care center, from January 2010 to July 2015. Patients with the following comorbidities were excluded: diabetes, viral hepatitis, patients who requested voluntarily their discharge from hospital, who were not treated with prednisone or pentoxifylline, co-infected with human immunodeficiency virus, or with diagnosis of hepatocarcinoma.

PROCEDURE

Demographic, clinical and biochemical data were collected. The following data were registered: amount of alcohol intake, development of ARF, hepatic encephalopathy, variceal bleeding, bacterial infections, suggestive changes of cirrhosis reported in

the ultrasonography. The nutritional status determined through the global subjective assessment (GSA) (8) at patient admission classified patients in one of three different categories: well-nourished, at risk of malnutrition, or severe malnourished. Treatment with prednisone or pentoxifylline was also verified. Also, the outcome (death or survival) since the admission to hospital until a 30-day follow-up was registered.

STATISTICAL ANALYSIS

Quantitative variables were resumed with mean and standard deviation when their distribution was normal, or with median and range in case of non-parametric distribution. For qualitative variables proportions and percentages were employed. The characteristics between groups were compared using Student's t test for independent samples or Mann-Whitney U test in case of continuous variables, and through Chi-squared test of Fisher's exact test for categorical variables. For the survival analysis, Kaplan-Meier curves and the log rank test were used. The association between risk factors and 30-day mortality was determined through hazard ratios (HR) and their respective 95% confidence intervals were calculated using Cox regression models. All those significant variables with a p value ≤ 0.05 identified in the univariate analysis were included in the multivariate analysis. The SPSS version 19.0 (Chicago, Illinois, USA) was used.

RESULTS

Seventy six patients were included, 72 (94.7%) were male, mean age was 43 ± 9.1 year-old, and 58 (76.3%) had changes compatible with cirrhosis in the ultrasonography. According to the GSA, 38 (50%) had severe malnutrition, 22 (28.9%) were at risk of malnutrition, and 16 (21.1%) were well-nourished. The overall 30-day mortality in this cohort was 46 patients (60.5%). The characteristics of patients at admission to hospital according to their outcome at 30 days of follow-up are summarized and compared in table I.

In the univariate analysis, the following variables were associated with 30-day mortality: concomitant cirrhosis (OR = 2.3; 95% CI: 1.5-3.4; $p < 0.0001$), development of hepatic encephalopathy (OR = 5.6; 95% CI: 2.5-12.5; $p < 0.0001$), development of ARF (OR = 6.2; 95% CI: 2.5-15.6; $p < 0.0001$), variceal bleeding (OR = 4.4; 95% CI: 1.7-11.3; $p < 0.0001$), bacterial infection (OR = 2.7; 95% CI: 1.3-5.8; $p = 0.004$), at risk of malnutrition according to the GSA (OR = 2.0; 95% CI: 1.2-3.3; $p = 0.01$), and severe malnutrition according to the GSA (OR = 5.8; 95% CI: 2.0-16.4; $p < 0.0001$). Neither therapy with prednisone nor therapy with pentoxifylline improved survival in patients with SAH. Neither was difference between the treatment groups (Table II).

When all significant variables in the univariate analysis were adjusted in a multivariate analysis, only severe malnutrition was associated with 30-day mortality (OR = 6.4; 95% CI: 1.9-22.1; $p = 0.003$) (Table III and Fig. 1).

Table I. Characteristics of patients at admission to hospital and comparison according to outcome at 30-day follow-up

Characteristic	Dead n = 46	Alive n = 30	p
Age in years	44.2 ± 8.7	41.0 ± 9.5	0.13
Male sex, n (%)	44 (95.7)	28 (93.3)	0.65
Maddrey's discriminant function	101.5 ± 73.5	73.0 ± 28.3	0.02
MELD	34.6 ± 7.7	27.4 ± 4.3	< 0.0001
MELD-Na	35.1 ± 5.6	30.0 ± 3.7	< 0.0001
Glasgow	10.3 ± 1.1	9.5 ± 1.1	0.001
ABIC	9.1 ± 1.8	7.9 ± 1.3	0.003
Alcohol (g/day)	361.0 ± 210.3	333.7 ± 134.8	0.49
Urea (mg/dl)	87.2 ± 67.8	38.2 ± 32.9	< 0.0001
Creatinine (mg/dl)	2.3 ± 1.1	1.4 ± 0.8	< 0.0001
Sodium (mEq/l)	129.6 ± 5.8	132.7 ± 4.7	0.01
Albumin (mg/dl)	1.7 ± 0.4	1.9 ± 0.3	0.009
Bilirubin (mg/dl)	24.6 ± 9.9	23.9 ± 11.3	0.70
AP (U/l)	200 ± 96	227 ± 88	0.22
GGT (U/l)	323 ± 252	322 ± 323	0.99
AST (U/l)	224 ± 174	183 ± 85	0.24
ALT (U/l)	77 ± 96	50 ± 28	0.14
Leukocytes (cel x 10 ³)	21.9 ± 9.9	16.5 ± 7.5	0.26
Neutrophiles (cel x 10 ³)	18.1 ± 9.4	16.5 ± 8.3	0.42
Hemoglobin (g/dl)	11.0 ± 2.9	11.7 ± 2.8	0.27
Platelets (cel x 10 ⁹)	171.1 ± 121.4	182.7 ± 107.3	0.67
Protrombin time (sec)	28.8 ± 16.1	22.6 ± 6.3	0.02
INR	2.5 ± 1.6	1.9 ± 0.5	0.02

ABIC: age-bilirubin-INR-creatinine; ALT: alanine aminotransferase; AP: alkaline phosphatase; AST: aspartate aminotransferase; GGT: gamma glutamyltransferase; INR: international normalized ratio; MELD: Model for End-stage Liver Disease; MELD-Na: Model for End-stage Liver Disease-Sodium. *t* de Student, Chi-squared: statistical significance $p < 0.05$.

DISCUSSION

In Mexico, mortality related to chronic liver disease is among the main causes of general mortality, occupying the fourth place (9), making it one of the countries with the highest rates of liver-related mortality (10). The Ministry of Health estimated an average of 25,000 deaths from cirrhosis between 2000 and 2010 (11). In Mexico, alcohol is the leading cause of cirrhosis, followed by hepatitis C and non-alcoholic steatohepatitis. In addition, when patients seek medical attention, they are often at advanced stage of the disease (Child-Pugh C) with obvious manifestations of decompensation, and they often continue to intake alcohol despite the diagnosis of liver disease. All these factors contributed to high mortality at productive age (12,13).

SAH is characterized by the rapid onset of jaundice and coagulopathy in patients with active and chronic alcohol intake (14). The reported mortality, as well as the response to therapy with steroids or pentoxifylline, is extremely variable among different populations.

Some authors report mortality greater than 50% at two months without specific treatment (steroids) (15-17). In France, treatment with prednisolone has been shown to be effective reducing mortality to 35% at six months of follow-up (18-20). Nevertheless, up to 40% of patients do not respond to steroid therapy, and particularly in these non-responder patients, mortality has been reported greater than 75% (16,21). On the other hand, several studies in Mexican population have found high mortality-rate and failure to steroid and pentoxifylline treatments. A cohort study in Mexican population found that near to 90% of patients with SAH were non-responders to steroid therapy according to the Lille model (Lille score value > 0.45 after seven days of treatment with prednisone) (22). A retrospective study by Garrido-García et al. found a mortality-rate as high as 59.9% at 28 days of follow-up, despite treatment with prednisone (23). In English population, the STOPAH trial, which included the greatest number of patients with SAH in a clinical trial, did not show usefulness of steroids or pentoxifylline; however, mortality-rate at 28 days in all groups

Table II. Univariate analysis comparing the clinical characteristics of surviving *versus* non-surviving patients during the 30-day follow-up

Characteristic	Dead n = 46	Alive n = 30	p	OR (95% CI)
Cirrhosis in the USG, n (%)	45 (97.8)	1 (3.3)	< 0.0001	2.3 (1.5-3.4)
Development of HE, n (%)	43 (93.5)	5 (16.7)	< 0.0001	5.6 (2.5-12.5)
Development of ARF, n (%)	38 (82.6)	4 (13.3)	< 0.0001	6.2 (2.5-15.6)
Development of VB, n (%)	27 (58.7)	4 (13.3)	< 0.0001	4.4 (1.7-11.3)
Development of infection, n (%)	25 (54.3)	6 (20.0)	0.004	2.7 (1.3-5.8)
GSA: nutritional status				
Well-nourished, n (%) [*]	3 (6.5)	16 (53.3)		
At risk of malnutrition, n (%) [†]	13 (28.2)	11 (36.7)	0.01 [§]	2.0 (1.2-3.3) [§]
Severe malnutrition, n (%) [‡]	30 (65.2)	3 (10.0)	< 0.0001 [†]	5.8 (2.0-16.4) [†]
Treatment				
Prednisone, n (%)	20 (51.3)	19 (48.7)	0.15	0.7 (0.4-1.1)
Pentoxifylline, n (%)	26 (70.3)	11 (29.7)		1.5 (0.9-2.6)

ARF: acute renal failure; GSA: global subjective assessment; HE: hepatic encephalopathy; OR: odds ratio; USG: ultrasonography; VB: variceal bleeding. [§]Comparison using Chi-squared between * and †. [†]Comparison using Chi-squared between * and ‡. Statistical significance $p \leq 0.05$.

Table III. Multivariate analysis to identify risk factors associated with early mortality in patients with severe alcoholic hepatitis

Characteristic	Dead n = 46	Alive n = 30	p	OR (IC 95%)
Cirrhosis in the USG, n (%)	45 (97.8)	1 (3.3)	0.31	3.4 (0.3-34.5)
Development of HE, n (%)	43 (93.5)	5 (16.7)	0.12	3.9 (0.7-21.0)
Development of ARF, n (%)	38 (82.6)	4 (13.3)	0.15	2.0 (0.8-5.1)
Development of VB, n (%)	27 (58.7)	4 (13.3)	0.70	1.1 (0.6-2.2)
Development of infection, n (%)	25 (54.3)	6 (20.0)	0.78	1.1 (0.6-2.1)
GSA: nutritional status				
Well-nourished, n (%) [*]	3 (6.5)	16 (53.3)		
At risk of malnutrition, n (%) [†]	13 (28.2)	11 (36.7)	0.06 [§]	3.5 (1.0-13.0) [§]
Severe malnutrition, n (%) [‡]	30 (65.2)	3 (10.0)	0.003 [†]	6.4 (1.9-22.1) [†]

ARF: acute renal failure; GSA: global subjective assessment; HE: hepatic encephalopathy; OR: odds ratio; USG: ultrasonography; VB: variceal bleeding. Cox regression model. [§]Comparison between * and †. [†]Comparison between * and ‡. Statistical significance $p \leq 0.05$.

was extremely low: 17% in the p placebo group, 14% in the prednisolone group, 19% in the pentoxifylline group, and 13% in the prednisolone plus pentoxifylline group (2).

Several studies have tried to explain which factors are related to a higher mortality in patients with SAH. The development of ARF is one of the most important mortality predictive factors (24). Interleukin-2 has been identified as a factor related to steroid treatment resistance (25). The amount of alcohol intake > 120 g/day has been also related to higher mortality-rate (1). Other factors associated with higher mortality-rate are age, raised serum creatinine, hyperbilirubinemia, leukocytosis, and also the synergistic effect of the development of two or three simultaneous complications as ARF, hepatic encephalopathy, or variceal bleeding (1,3).

In the univariate analysis, our study confirmed ARF, variceal bleeding, hepatic encephalopathy, and infection are clinical factors related to a higher mortality-rate in patients with SAH.

Malnutrition is a prevalent comorbid condition in Mexican alcoholic patients. The prevalence of malnutrition and its degree correlates with the severity of chronic liver disease and its complications (26). But, until now no study has previously evaluated the impact of malnutrition on mortality of Mexican patients with SAH. Our study shows that severe malnutrition is a determinant factor which explains the high mortality-rate in Mexican patients with SAH. As the Kaplan-Meier curves and the multivariate analysis show, malnutrition resulted to be the most important risk factor related to high early mortality in these patients.




Figure 1.

Kaplan-Meier curves showing 30-day survival according to nutritional status in a cohort of patients with severe alcoholic hepatitis. Cox regression, $p = 0.008$. Adjusted model for the following co-variables: development of hepatic encephalopathy, variceal bleeding, acute renal failure, infection, concomitant cirrhosis on the ultrasonography.

The prevalence of malnutrition in patients with cirrhosis is widely variable; it has been reported from 25% to 80%, depending on the clinical severity of the disease and the specific evaluation method used (27-29).

The European Society for Clinical Nutrition and Metabolism (ESPEN) guidelines recommend clinical methods, as the GSA, to evaluate the nutritional status in patients with liver diseases (30,31). The GSA is a routinely used tool in our hospital to evaluate nutritional status in patients with liver diseases. In our study, a high frequency of severe malnutrition was found, which is in agreement with previous findings reported by other authors (27-29).

The liver participates in the caloric homeostasis regulation (32). Patients with liver disease are susceptible to malnutrition due to several factors such as poor ingestion, fat malabsorption, intestinal loss of proteins, decreased protein synthesis, hypermetabolic state, symptoms as nausea, vomiting, early satiety, insulin resistance, gastroparesis, ascites, bacterial overgrowth (33). There is also over-regulation of inflammatory mediators that interfere with appetite, such as the tumor necrosis factor- α (34), which is significantly elevated in patients with SAH (14).

Sarcopenia is a common complication in patients with chronic liver disease and it worsens as chronic liver disease worsens (35,36); likewise, malnutrition is a predictor of morbidity and mortality in patients with chronic liver disease (34). Similarly to our finding about the association between malnutrition and higher mortality at 30 days, other authors have found in different populations a relationship between malnutrition and higher mortality-rate at 30-day, 6-month and 12-month follow-up in patients with SAH (5-7).

The American Association for the Study of Liver Disease and the European Association for the Study of the Liver recommend enteral nutrition with the objective of preserving the integrity of

the intestinal barrier and avoiding the pathological increase in intestinal permeability, as well as to prevent the risk infection due to bacterial translocation infection, promote the anabolism to preserve muscle mass and prevent sarcopenia, and restore deposits of glutathione, a potent cellular antioxidant which is severely depleted in SAH (37).

CONCLUSIONS

This study confirms that nutritional status is an important factor associated with early mortality (first 30 days) in patients with SAH. Severe malnutrition clearly explains the high mortality observed in Mexican patients with SAH. The evaluation of nutritional status is essential as part of the initial assessment of patients with SAH since it behaves as a prognostic factor. Strategies to prevent nutritional deterioration are crucial in order to improve the survival of these patients.

REFERENCES

- Altamirano J, Higuera-de-la-Tijera F, Duarte-Rojo A, Martínez-Vázquez MA, Abraides JG, Herrera-Jiménez LE, et al. The amount of alcohol consumption negatively impacts short-term mortality in Mexican patients with alcoholic hepatitis. *Am J Gastroenterol* 2011;106:1472-80.
- Thursz MR, Richardson P, Allison M, Austin A, Bowers M, Day CP, et al. Prednisolone or pentoxifylline for alcoholic hepatitis. *N Engl J Med* 2015;372:1619-28.
- Higuera-de-la-Tijera MF, Pérez-Hernández JL, Servín-Caamaño AI, Serralde-Zúñiga AE, Cruz-Palacios A. The amount of alcohol intake, upper gastrointestinal bleeding, acute renal failure and hepatic encephalopathy as the risk factors implied in the increase of patients with alcoholic hepatitis. *Rev Gastroenterol Mex* 2009;74:306-13.
- Göktürk HS, Selçuk H. Importance of malnutrition in patients with cirrhosis. *Turk J Gastroenterol* 2015;26:291-6.
- Mendenhall CL, Tosch T, Weesner RE, Garcia-Pont P, Goldberg SJ, Kiernan T, et al. VA cooperative study on alcoholic hepatitis. II: prognostic significance of protein-calorie malnutrition. *Am J Clin Nutr* 1986;43:213-8.
- Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a department of veterans affairs cooperative study. *Hepatology* 1993;17:564-76.
- Mendenhall CL, Moritz TE, Roselle GA, Morgan TR, Nemchausky BA, Tamburro CH, et al. Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. *J Parenter Enteral Nutr* 1995;19:258-65.
- Detsky A, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, et al. What is Subjective Global Assessment of nutritional status? 1987. *Classical article. Nutr Hosp* 2008;23:400-7.
- Dirección General de Información en Salud. Mortalidad. Available from: http://www.dgis.salud.gob.mx/contenidos/sinais/e_mortalidadgeneral.html
- World Health Organization. Global Health Observatory (GHO) data. Global Information System on Alcohol and Health (GISAH). Available from: <http://www.who.int/gho/alcohol/en/>
- Sistema Nacional de Información en Salud. Secretaría de Salud. Available from: <http://www.sinais.salud.gob.mx/publicaciones/index.html>
- Campollo O, Valencia-Salinas JJ, Berumen-Arellano A, Pérez-Aranda MA, Panduro-Cerda A, Segura-Ortega J. Epidemiological characteristics of liver cirrhosis at the Hospital Civil of Guadalajara. *Salud Publica Mex* 1997;39:195-200.
- Roman S, Zepeda-Carrillo EA, Moreno-Luna LE, Panduro A. Alcoholism and liver disease in Mexico: genetic and environmental factors. *World J Gastroenterol* 2013;19:7972-82.
- Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. *N Engl J Med* 2009;360:2758-69.

15. Haber PS, Warner R, Seth D, Gorrell MD, McCaughan GW. Pathogenesis and management of alcoholic hepatitis. *J Gastroenterol Hepatol* 2003;18:1332-44.
16. Mathurin P, Abdelnour N, Ramond MJ, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. *Hepatology* 2003;38:1363-9.
17. McCullough AJ, O'Connor JF. Alcoholic liver disease: proposed recommendations for the American College of Gastroenterology. *Am J Gastroenterol* 1998;93:2022-36.
18. Carithers RL, Herlong F, Diehl AM, Shaw EW, Combes B, Fallon HJ, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. *Ann Intern Med* 1989;110:685-90.
19. Mathurin P, Duchatelle V, Ramond MJ, Degott C, Bedossa P, Erlinger S, et al. Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. *Gastroenterology* 1996;110:1847-53.
20. Mathurin P, Mendenhall CL, Carithers RL Jr, Ramond MJ, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. *J Hepatol* 2002;36:480-7.
21. Louvet A, Naveau S, Abdelnour M, Ramond MJ, Díaz E, Fartoux L, et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. *Hepatology* 2007;45:1348-54.
22. Ruiz-Zavala A, Gil-Rojas N, Higuera-de-la-Tijera MF. Response to prednisone in Mexican patients with alcoholic hepatitis in a period of four years in the Hospital General de México. *Ann Hepatol* 2012;11:602.
23. Garrido-García JR, Sánchez-Hernández G, Melchor-López A, Elizalde-Barrera CI, Sánchez-Vargas L. Pentoxifilina versus esteroide en la sobrevivencia a corto plazo en hepatitis aguda alcohólica severa. *Med Int Mex* 2012;28:227-33.
24. Pudukollu R, Gopalswamy N. The hepatorenal syndrome. *Med Clin North Am* 1990;74:933-44.
25. Di Mambro AJ, Parker R, McCune A, Gordon F, Dayan CM, Collins P. In vitro steroid resistance correlates with outcome in severe alcoholic hepatitis. *Hepatology* 2011;53:1316-22.
26. Landa-Galván HV, Milke-García MP, León-Oviedo C, Gutiérrez-Reyes G, Higuera-de-la-Tijera F, Pérez-Hernández JL, et al. Nutritional assessment of alcoholic liver cirrhotic patients treated in the liver Clinic of the Mexico's General Hospital. *Nutr Hosp* 2012;27:2006-14.
27. Figueiredo FAF, Perez RM, Freitas MM, Kondo M. Comparison of three methods of nutritional assessment in liver cirrhosis: subjective global assessment, traditional nutritional parameters, and body composition. *J Gastroenterol* 2006;41:476-82.
28. Castellanos-Fernández M, Santana-Porbén S, García-Jordá E, Rodríguez-de Miranda A, Barreto-Penié J, López-Díaz Y, et al. Influence of hyponutrition on occurrence of complications and mortality among cirrhosis patients. *Nutr Hosp* 2008;23:68-74.
29. Carvalho L, Parise ER. Evaluation of nutritional status of nonhospitalized patients with liver cirrhosis. *Arq Gastroenterol* 2006;43:269-74.
30. Plauth M, Cabré E, Riggio O, Assis-Camilo M, Pirlich M, Kondrup J, et al. ESPEN guidelines on enteral nutrition: liver disease. *Clin Nutr* 2006;25:285-94.
31. Plauth M, Cabré E, Campillo B, Kondrup J, Marchesini G, Schütz T, et al. ESPEN guidelines on parenteral nutrition: hepatology. *Clin Nutr* 2009;28:436-44.
32. Purnak T, Yilmaz Y. Liver disease and malnutrition. *Best Pract Res Clin Gastroenterol* 2013;27:619-29.
33. Aceves-Martins M. Nutritional care for patients with cirrhosis. *Nutr Hosp* 2014;29:246-58.
34. Cheung K, Lee SS, Raman M. Prevalence and mechanisms of malnutrition in patients with advanced liver disease, and nutrition management strategies. *Clin Gastroenterol Hepatol* 2012;10:117-25.
35. O'Brien A, Williams R. Nutrition in end-stage liver disease: principles and practice. *Gastroenterology* 2008;134:1729-40.
36. Dasarathy S. Consilience in sarcopenia of cirrhosis. *J Cachexia Sarcopenia Muscle* 2012;3:225-37.
37. Koretz RL. The evidence for the use of nutritional support in liver disease. *Curr Opin Gastroenterol* 2014;30:208-14.